Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

Games, D; Bard, F; Grajeda, H; Guido, T; Khan, K; Soriano, F; Vasquez, N; Wehner, N; Johnson-Wood, K; Yednock, T; Seubert, P; Schenk, D

Games, D; Bard, F; Grajeda, H; Guido, T; Khan, K; Soriano, F; Vasquez, N; Wehner, N; Johnson-Wood, K; Yednock, T; Seubert, P; Schenk, D.

Affiliation

Games D; Elan Pharmaceuticals, 800 Gateway Blvd., So. San Francisco, CA 94080, USA. dgames@elanpharma.com

Ann N Y Acad Sci ; 920: 274-84, 2000.

Article in En | MEDLINE | ID: mdl-11193164

Subject(s)

Alzheimer Disease/pathology; Alzheimer Disease/prevention & control; Amyloid beta-Peptides/immunology; Amyloid beta-Peptides/metabolism; Peptide Fragments/immunology; Peptide Fragments/metabolism; Alzheimer Disease/microbiology; Amyloidosis/prevention & control; Animals; Antibody Formation; Astrocytes/pathology; Brain/pathology; Gliosis; Hippocampus/pathology; Humans; Immunotherapy; Mice; Mice, Transgenic; Neurites/pathology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Amyloid beta-Peptides / Alzheimer Disease Limits: Animals / Humans Language: En Journal: Ann N Y Acad Sci Year: 2000 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links